| Commercialization and regulation of regenerative medicine products: Promises, advances and challenges N Beheshtizadeh, M Gharibshahian, Z Pazhouhnia, M Rostami, AR Zangi, ... Biomedicine & Pharmacotherapy 153, 113431, 2022 | 32 | 2022 |
| Combining liquisolid and co-grinding techniques to enhance the dissolution rate of celecoxib NM Nazem, J Shokri, N Nourani, AR Zangi, M Lam, A Nokhodchi, ... Journal of Pharmaceutical Innovation 18 (1), 300-309, 2023 | 6 | 2023 |
| Immobilized nanoparticles-mediated enzyme therapy; promising way into clinical development AR Zangi, A Amiri, F Borzouee, R Bagherifar, P Pazooki, H Hamishehkar, ... Discover Nano 18 (1), 55, 2023 | 4 | 2023 |
| Non-viral and viral delivery systems for hemophilia A therapy: recent development and prospects AR Zangi, A Amiri, P Pazooki, F Soltanmohammadi, H Hamishehkar, ... Annals of Hematology 103 (5), 1493-1511, 2024 | 1 | 2024 |
| Current knowledge of hybrid nanoplatforms composed of exosomes and organic/inorganic nanoparticles for disease treatment and cell/tissue imaging F Soltanmohammadi, AM Gharehbaba, AR Zangi, K Adibkia, ... Biomedicine & Pharmacotherapy 178, 117248, 2024 | | 2024 |
| Novel synthesized ionizable lipid for LNP-mediated P2X7siRNA to inhibit migration and induce apoptosis of breast cancer cells SH Kiaie, AR Zangi, M Sheibani, S Hemmati, B Baradaran, H Valizadeh Purinergic Signalling, 1-14, 2024 | | 2024 |
| Generation of mouse model of hemophilia a by introducing novel mutations, using crispr/nickase gene targeting system M Shamsara, A Jamshidizad, A Rahim-Tayfeh, M Davari, AR Zangi, ... Cell Journal (Yakhteh) 25 (9), 655, 2023 | | 2023 |
